.jpeg)
Ipilimumab success rate
Ipilimumab)Combined with other drugs such as pembrolizumab (Pembrolizumab) or nilLowMonocab (Nivolumab) has shown positive results. In the CheckMate 204 trial, the 3-year overall survival rate of patients with melanoma and asymptomatic brain metastases treated with ipilimumab combined with ipilimumab was 71.9%. In the same clinical setting of the Anti-PD-1 Brain Collaboration (ABC) study, the 5-year survival rate was 51%. These data indicate that ipilimumab combined with other immunotherapy drugs has a high success rate in the treatment of melanoma, especially in terms of long-term survival. But each patient's situation is unique, so treatment decisions should be based on the patient's specific situation and the doctor's recommendations.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
